Food and Beverage Marketing on California High School Campuses Survey: Findings and Recommendations

Assesses marketing of food and beverages at 20 California public high schools. Provides recommendations for eliminating commercial influences that promote unhealthy foods and beverages, consumer education, and establishing business partnership guidelines

The Federal Child Nutrition Commodity Program: A Report on Nutritional Quality

Examines the types of food California schools order through the USDA Child Nutrition Commodity Program and how they affect the nutritional value of school meals. Includes policy recommendations for ensuring that meals meet nutritional guidelines

Far‐Red Organic Fluorophores Contain a Fluorescent Impurity

Far‐red organic fluorophores commonly used in traditional and super‐resolution localization microscopy are found to contain a fluorescent impurity with green excitation and near‐red emission. This near‐red fluorescent impurity can interfere with some multicolor stochastic optical reconstruction microscopy/photoactivated localization microscopy measurements in live cells and produce subtle artifacts in chemically fixed cells. We additionally describe alternatives to avoid artifacts in super‐resolution localization microscopy. A near‐red fluorescent impurity is characterized in several commonly used far‐red fluorescent dyes. This impurity can lead to artifacts in live‐cell multicolor super‐resolution measurements, subtle artifacts in chemically fixed cells, and highlights the importance of controls in super‐resolution imaging.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/108014/1/2240_ftp.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/108014/2/cphc_201402002_sm_miscellaneous_information.pd

Simplified marker sets for the calculation of centre of mass location during bend sprinting

Simplified marker sets for the calculation of whole body centre of mass (CoM) location and associated variables (velocity, touchdown distance and turn of CoM) used in the analysis of bend sprinting performance were examined. CoM related variables were compared between a whole-body (13 segment), lower limb and trunk and lower limb model. Both simplified models showed strong agreement with whole-body CoM (Intraclass correlation: 0.873 - 0.998). The lower limb and trunk model (LLT) was the most accurate representation of whole body calculations, with acceptably low differences in all variables examined. Therefore, the LLT model is recommended for future use

Measurement of bend sprinting kinematics with three-dimensional motion capture : a test-retest reliability study

Sprint velocity decreases on the bend when compared with the straight, therefore understanding technique during bend sprinting could have important implications for aiding race performance. Few bend sprinting studies have used optoelectronic cameras to investigate kinematic variables. Limited published evidence regarding the reliability of marker sets in conditions representative of elite bend sprinting makes model selection difficult. Therefore, a test-retest protocol was conducted to establish the reliability and minimum detectable difference of a lower limb and trunk marker set during bend sprinting (radius: 36.5 m). Six participants completed five, 60 m trials at maximum effort, with data collected at 38 - 45 m. This was repeated 2 - 7 days later. Spatio-temporal (e.g. contact time) and kinematic variables (e.g. peak joint angles) were evaluated. Intraclass correlation coefficients (ICC) were used to determine the between- and within-day reliability. Between-day reliability (ICC 3, k) was fair to excellent for all variables. Compared to between-day, within-day reliability demonstrated stronger agreement for the majority of variables. Thus, same-day data collection is preferable. It has been established that the marker set is reliable for future use. In addition, the minimal detectable difference was calculated which serves as useful reference for future research in bend sprinting

Untitled

Sarah Stone \u2794 (Untitled

Clinically relevant enhancement of human sperm motility using compounds with reported phosphodiesterase inhibitor activity

STUDY QUESTION: Can we identify compound(s) with reported phosphodiesterase inhibitor (PDEI) activity that could be added to human spermatozoa in vitro to enhance their motility without compromising other sperm functions? SUMMARY ANSWER: We have identified several compounds that produce robust and effective stimulation of sperm motility and, importantly, have a positive response on patient samples. WHAT IS KNOWN ALREADY: For >20 years, the use of non-selective PDEIs, such as pentoxifylline, has been known to influence the motility of human spermatozoa; however, conflicting results have been obtained. It is now clear that human sperm express several different phosphodiesterases and these are compartmentalized at different regions of the cells. By using type-specific PDEIs, differential modulation of sperm motility may be achieved without adversely affecting other functions such as the acrosome reaction (AR). STUDY DESIGN, SIZE, DURATION: This was a basic medical research study examining sperm samples from normozoospermic donors and subfertile patients attending the Assisted Conception Unit (ACU), Ninewells Hospital Dundee for diagnostic semen analysis, IVF and ICSI. Phase 1 screened 43 commercially available compounds with reported PDEI activity to identify lead compounds that stimulate sperm motility. Samples were exposed (20 min) to three concentrations (1, 10 and 100 µM) of compound, and selected candidates (n = 6) progressed to Phase 2, which provided a more comprehensive assessment using a battery of in vitro sperm function tests.  PARTICIPANTS/MATERIALS, SETTING, METHODS: All healthy donors and subfertile patients were recruited at the Medical Research Institute, University of Dundee and ACU, Ninewells Hospital Dundee (ethical approval 08/S1402/6). In Phase 1, poor motility cells recovered from the 40% interface of the discontinuous density gradient were used as surrogates for patient samples. Pooled samples from three to four different donors were utilized in order to reduce variability and increase the number of cells available for simultaneous examination of multiple compounds. During Phase 2 testing, semen samples from 23 patients attending for either routine diagnostic andrology assessment or IVF/ICSI were prepared and exposed to selected compounds. Additionally, 48 aliquots of prepared samples, surplus to clinical use, were examined from IVF (n = 32) and ICSI (n = 16) patients to further determine the effects of selected compounds under clinical conditions of treatment. Effects of compounds on sperm motility were assessed by computer-assisted sperm analysis. A modified Kremer test using methyl cellulose was used to assess sperm functional ability to penetrate into viscous media. Sperm acrosome integrity and induction of apoptosis were assessed using the acrosomal content marker PSA-FITC and annexin V kit, respectively. MAIN RESULTS AND THE ROLE OF CHANCE: In Phase 1, six compounds were found to have a strong effect on poor motility samples with a magnitude of response of ≥60% increase in percentage total motility. Under capacitating and non-capacitating conditions, these compounds significantly (P ≤ 0.05) increased the percentage of total and progressive motility. Furthermore, these compounds enhanced penetration into a cervical mucus substitute (P ≤ 0.05). Finally, the AR was not significantly induced and these compounds did not significantly increase the externalization of phosphatidylserine (P = 0.6, respectively). In general, the six compounds maintained the stimulation of motility over long periods of time (180 min) and their effects were still observed after their removal. In examinations of clinical samples, there was a general observation of a more significant stimulation of sperm motility in samples with lower baseline motility. In ICSI samples, compounds #26, #37 and #38 were the most effective at significantly increasing total motility (88, 81 and 79% of samples, respectively) and progressive motility (94, 93 and 81% of samples, respectively). In conclusion, using a two-phased drug discovery screening approach including the examination of clinical samples, 3/43 compounds were identified as promising candidates for further study. LIMITATIONS, REASONS FOR CAUTION: This is an in vitro study and caution must be taken when extrapolating the results. Data for patients were from one assessment and thus the robustness of responses needs to be established. The n values for ICSI samples were relatively small. WIDER IMPLICATIONS OF THE FINDINGS: We have systematically screened and identified several compounds that have robust and effective stimulation (i.e. functional significance with longevity and no toxicity) of total and progressive motility under clinical conditions of treatment. These compounds could be clinical candidates with possibilities in terms of assisted reproductive technology options for current or future patients affected by asthenozoospermia or oligoasthenozoospermia